Scynexis & Anacor Report Positive Results for Sleeping Sickness Drug
The studies demonstrated the drug's safety and its ability to cross the blood-brain barrier, proving it effective against the disease in its first two stages.
Biotech company Scynexis in Research Triangle Park, North Carolina, and Anacor Pharmaceuticals in Palo Alto, California, have announced the successful completion of pre-clinical studies of oral drug candidate SCYX-7158 (AN5568), used to treat sleeping sickness. The new compound will soon be advanced to Phase I human clinical trials.
The studies demonstrated the drug's safety and its ability to cross the blood-brain barrier, proving it effective against the disease in its first two stages.
The study, published in scientific journal PLoS Neglected Tropical Diseases, also showed that the drug could change the way of treating sleeping sickness by reducing its incidence in humans, and contributing to elimination of the disease.
Related News
-
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News PSCI launches progressive position on the use of Horseshoe Crabs
A quarterly series of articles about responsible supply chain management from the PSCI. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research. -
News Thermo Fisher Scientific opens new steriles drug manufacturing site in Singapore
The life science service and instrument provider have opened their new Singapore-based steriles drug manufacturing facility with the goal of bringing increased development and manufacturing capabilities for critical medicines to the APAC region. -
News Medicines for All receive $18.7 million grant for expansion of global access to lifesaving medication
Funded by the Bill & Melinda Gates Foundation, the Virginia Commonwealth University-based research-related institute will use the grant to expand on its current capabilities of bringing lifesaving medications around the world, as well as working on 14 ...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance